0.2139

0.88% -0.003

Processa Pharmaceuticals Inc (PCSA)

Overview News Price History Financials Discussions Forecast Stock Split

Processa Pharmaceuticals Inc stock is traded at $0.2139, with a volume of 798.72K. It is down -0.88% in the last 24 hours and down -17.31% over the past month. Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Previous Close:

$0.2169

Open:

$0.21

24h Volume:

798.72K

Relative Volume:

0.05

Market Cap:

$2.54M

Revenue:

Net Income/Loss:

$-11.53M

P/E Ratio:

-0.0444

EPS:

-4.82

Net Cash Flow:

$-11.12M

1W Performance:

-6.48%

1M Performance:

-17.31%

6M Performance:

-73.39%

1Y Performance:

-87.43%

1-Day Range:

$0.21

$0.22

1-Week Range:

$0.20

$0.248

52-Week Range:

$0.15

$3.10

Processa Pharmaceuticals Inc Stock (PCSA) Company Profile

Name

Processa Pharmaceuticals Inc

Sector

Healthcare (1170)

Industry

Biotechnology (659)

Phone

443-776-3133

Address

7380 COCA COLA DRIVE, HANOVER

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

PCSA's Discussions on Twitter

Compare PCSA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PCSA Processa Pharmaceuticals Inc	0.214	6.36M	0	-11.53M	-11.12M	-4.82
VRTX Vertex Pharmaceuticals Inc	468.38	123.00B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	550.50	59.66B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	322.11	41.84B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	569.12	33.98B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	289.00	27.67B	3.81B	-644.79M	-669.77M	-6.24

Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-25-24	Initiated	H.C. Wainwright	Buy

Processa Pharmaceuticals Inc Stock (PCSA) Latest News

Jul 16, 2025

How Processa Pharmaceuticals Inc. stock performs during market volatilityTrend Following Trades - Newser

Jul 16, 2025

Jul 15, 2025

Processa Pharmaceuticals Reschedules Annual Shareholder Meeting - TipRanks

Jul 15, 2025

Processa Pharmaceuticals to reconvene annual meeting after achieving quorum By Investing.com - Investing.com South Africa

Jul 15, 2025

Processa Pharmaceuticals to reconvene annual meeting after achieving quorum - Investing.com

Jul 15, 2025

Why Processa Pharmaceuticals Inc. stock attracts strong analyst attentionCarefully Curated High Return Stocks - Newser

Jul 15, 2025

What makes Processa Pharmaceuticals Inc. stock price move sharplyRisk Managed Trading Strategy - Newser

Jul 15, 2025

Jul 11, 2025

Processa Pharmaceuticals: Betting on Catalyst-Driven Value Acceleration - AInvest

Jul 11, 2025